Treatment of insulin resistance in diabetes mellitus

被引:65
作者
Lebovitz, HE [1 ]
Banerji, MA [1 ]
机构
[1] SUNY Hlth Sci Ctr, Dept Med, Brooklyn, NY 11203 USA
关键词
insulin; diabetes mellitus; obesity;
D O I
10.1016/j.ejphar.2004.02.051
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Insulin resistance is a condition in which the glycemic response to insulin is less than normal. The change in insulin sensitivity leads to several sets of responses. One set effects the beta cell and leads to its accelerated destruction and the development of diabetes mellitus. The other set generates a series of nontraditional cardiovascular risk factors that result in accelerated atherosclerosis. Both of these sets of responses may have impacts on other tissues such as the nervous system. Insulin resistance is probably the result of increased visceral adiposity with increased release of free fatty acids and cytokines and a decreased release of adiponectin. Treatment of insulin resistance and its associated abnormalities can be achieved by lifestyle modification which results in weight loss, by drugs that reverse the abnormal adipocyte effects. by drugs that improve insulin sensitivity at the level of the liver and by anti-inflammatory agents that block activation of the nuclear factor kappa B cascade. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:135 / 146
页数:12
相关论文
共 98 条
[1]   Visceral fat and race-dependent health risks in obese nondiabetic premenopausal women [J].
Albu, JB ;
Murphy, L ;
Frager, DH ;
Johnson, JA ;
PiSunyer, FX .
DIABETES, 1997, 46 (03) :456-462
[2]  
[Anonymous], 1995, Diabetes, V44, P1249
[3]  
[Anonymous], ENDOCRINOLOGY
[4]   Peroxisome proliferator-activated receptor β regulates acyl-CoA synthetase 2 in reaggregated rat brain cell cultures [J].
Basu-Modak, S ;
Braissant, O ;
Escher, P ;
Desvergne, B ;
Honegger, P ;
Wahli, W .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (50) :35881-35888
[5]   Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women [J].
Buchanan, TA ;
Xiang, AH ;
Peters, RK ;
Kjos, SL ;
Marroquin, A ;
Goico, J ;
Ochoa, C ;
Tan, S ;
Berkowitz, K ;
Hodis, HN ;
Azen, SP .
DIABETES, 2002, 51 (09) :2796-2803
[6]   The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: A placebo-controlled randomized clinical trial [J].
Caballero, AE ;
Saouaf, R ;
Lim, SC ;
Hamdy, O ;
Abou-Elenin, K ;
O'Connor, C ;
LoGerfo, FW ;
Horton, ES ;
Veves, A .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2003, 52 (02) :173-180
[7]   Peroxisome proliferator-activated receptor γ ligands increase release of nitric oxide from endothelial cells [J].
Calnek, DS ;
Mazzella, L ;
Roser, S ;
Roman, J ;
Hart, CM .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (01) :52-57
[8]   Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects -: The BIGPRO1 study [J].
Charles, MA ;
Morange, P ;
Eschwège, E ;
André, P ;
Vague, P ;
Juhan-Vague, I .
DIABETES CARE, 1998, 21 (11) :1967-1972
[9]   Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes [J].
Chu, NV ;
Caulfield, M ;
Kong, APS ;
Mudaliar, SR ;
Kim, DD ;
Reitz, R ;
Armstrong, D ;
Henry, RR ;
Baxi, S ;
Reaven, PD ;
Deutsch, R .
DIABETES CARE, 2002, 25 (03) :542-549
[10]   Peroxisome proliferator-activated receptors (PPARs) and peroxisomes in rat cortical and cerebellar astrocytes [J].
Cristiano, L ;
Bernardo, A ;
Cerù, MP .
JOURNAL OF NEUROCYTOLOGY, 2001, 30 (08) :671-683